Trial Profile
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Trotabresib (Primary)
- Indications Adenocarcinoma; Astrocytoma; Basal cell cancer; Carcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Glioblastoma; Glioma; Marginal zone B-cell lymphoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Salivary gland cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 29 Feb 2024 Planned End Date changed from 22 Mar 2026 to 15 Jun 2026.
- 29 Feb 2024 Planned primary completion date changed from 22 Mar 2024 to 15 Jun 2024.
- 09 Jan 2024 Planned End Date changed from 27 Apr 2024 to 22 Mar 2026.